Competing interests
J-LV, ischemia, sepsis, Sepsis
LUNG, ISCHEMIA, SEPSIS, SEPSIS
MS reports a clinical study grant paid to his institution from Gentian, consulting fees paid to his institution (Biotest, Matisse and Volition) and to himself (deePull), and speaker fees paid to his institution from Fresenius. He reports payments for participation on Data Safety Monitoring or Advisory Boards to himself (Safeguard Biosystems, Aptarion, and Roche Diagnostics) and to his institution (NewB). MS’s institution (University College London) has been granted a patent on an ischemia drug and has another pending on a sepsis product. MS is an unpaid council member of the International Sepsis Forum and his Institute has stock in Deltex Medical; AT reports consultancy fees and speaker fees from Biotest AG, Janssen, MSD and Pfizer. CCH, SW, AS, SK, KJ, TH, PL, AW-D and JS are employees of Biotest AG; JS is an executive board member of Biotest AG which has received a German Government Grant (Bundesministerium für Bildung und Forschung [BMBF]); J-LV is a Journal Editor. He reports no other conflicts of interest; TW reports consultancy fees, speaker fees, and meeting travel support from Biotest AG. His institution has received a grant from the German Ministry of Research and Education. He is Past President of the European Respiratory Society, Chairman of the Board of Trustees of the German Lung Foundation and Chairman of the Board of Trustees of the German Sepsis Foundation.